Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy

NCT02388295 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02388295
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02388295 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Multicenter, Randomized, Parallel-Group Study to Assess the Safety, Tolerability, Pharmacokinetics, Biomarker Effects, Efficacy, and Effect on Microglia Activation, as Measured by Positron Emission Tomography, of AZD3241 in Subjects With Multiple System Atrophy
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
April 27, 2015
Completion date
September 19, 2016
Enrollment
59 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

multiple system atrophy, msa